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Affinity labeling has been a powerful tool for the biochemical characterization of sparse
molecules which bind to a ligand probe in a specific, high-affinity manner. The rat pancreatic
acinar cell receptor for cholecystokinin (CCK), the major physiologic hormonal stimulant of
pancreatic exocrine secretion, has been the target of such investigation. Of interest, affinity-
labeling studies have identified two distinct plasma membrane glycoproteins as candidates to
represent this receptor. The initial candidate, which was identified using 1251-Bolton Hunter-
labeled CCK-33 as probe, migrates on a SDS-polyacrylamide gel as a broad band in the Mr =
80,000 range. Subsequently, using shorter probes in which the site of covalent attachment was
closer to the receptor-binding domain of the probe, a band of Mr = 85,000-95,000 was
specifically labeled. Deglycosylation and protease-peptide mapping demonstrated that these
bands represent distinct molecules. Using "intrinsic" probes of the receptor, in which a
photolabile residue was sited within the pharmacophoric domain of the ligand, attention was
focused on the latter candidate as representing the binding protein. Insight into the relation-
ship between these proteins as they reside in the plasma membrane was contributed by labeling
with a "topographical mapping" probe, which incorporates a flexible spacer ofvariable length
between a CCK-like ligand and a photolabile residue. This procedure confirmed that these two
minormembrane proteins are spatially associated with eachother. In addition to the identifica-
tion of proteins which represent the hormone-binding protein and proteins associated with it,
affinity-labeling approaches can provide structural information about post-translational modifi-
cations of these proteins, which clearly complement and extend the primary amino acid
sequence data now made available by receptor cDNA cloning. There are data to support the
glycosylation and phosphorylation ofthe ratpancreatic CCK receptor. In addition, it is possible
to use photoaffinity labelingwith "intrinsic" probes to label directly domains and residues in the
receptor which are critical to agonist binding.
Cholecystokinin (CCK) is the major physiologic hormonal stimulant ofpancreatic
exocrine secretion. Its effects are initiated by a high-affinity, specificbinding interac-
tion with a plasmalemmal receptor for this hormone on the pancreatic acinar cell.
Although CCKwas one ofthe earliest recognized gastrointestinal hormones, discov-
ered over60years ago [1], thecharacterization ofreceptors forthishormone is avery
recent phenomenon. The reason forthis delay relates to the extremely small number
of these receptors on target cells, and the methodological difficulties in characteriz-
ing these.
As is the case for many hormone receptors, the earliest characterization of the
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CCK receptor was functional, using classical pharmacological techniques ofdescrip-
tion of the biological response to structural analogs of the native hormone. These
studies clearly localized thebiologically active domain ofcholecystokinin peptides to
their carboxyl-terminal heptapeptide-amide [2]. This domain is shared by all molecu-
lar forms ofthis hormone and is the domainwhich defines the CCK/gastrin family of
hormones. Gastrin shares the identical carboxyl-terminal pentapeptide amide with
CCK and indeed can interactwith CCK receptors as aweak agonist [3].
Currently, receptors for this family of hormones can be classified into two main
groups [4]: (i) the type A, or "alimentary" type ofreceptor, present on the pancreatic
acinar cell, the gallbladder muscularis smooth muscle, pyloric smooth muscle, and a
fewselect brainnuclei; and (ii) the type B/gastrin receptor,which isthepredominant
type in the "brain" and on the gastric parietal cell. The type A receptor, which is the
focus of this review, is the most selective receptor in the CCK-gastrin family,
requiring the entire carboxyl-terminal heptapeptide, including a sulfated tyrosine for
high-affinity binding. The type B and gastrin receptors require only the carboxyl-
terminal tetrapeptide for high-affinity binding. There has been considerable discus-
sion as to whether the type B and gastrin receptors represent the same or different
receptors [5]. Subtle affinity and potencydifferences havebeen reported fordifferent
structural analogs of CCK and gastrin at these two receptors; however, these
observed differences may represent only differences in species and tissues, or
differences in laboratory technique. Although a variety of receptor antagonists can
clearly distinguish between the type A and type B/gastrin receptors [6], none
reported to date can distinguish between the type B receptor and the gastrin
receptor.
DESIGN OF CCK RECEPTOR PROBES
The chemical structure ofthe carboxyl-terminal domain ofCCK has been respon-
sible for some of the difficulty in the direct characterization of this receptor. This
region includes a sulfated tyrosyl residue which is critical for high-affinity binding,
and which is labile in acidic conditions. The carboxyl-terminal phenylalanine-amide
is also important for high-affinity binding and is base-labile. Present in this region of
the peptide are two methionines, which are sensitive to oxidation, markedly interfer-
ing with binding and biological activity. These structural features of CCK made the
development of a high specific radioactivity probe based on the structure of the
native hormonal ligand a challenge.
Radioiodination is the technique ofchoice to radiolabel a peptide ligand in order
to achieve the high specific radioactivity which is necessary to characterize the small
number ofreceptors present on native targets ofthis hormone (on the order of5,000
molecules per cell) [7]. Native CCK cannot be radioiodinated oxidatively due to the
absence of an unsubstituted tyrosine and to the presence of the critical methionine
residues. The other major method for radioiodination utilizes acylation with a
radioiodinated residue, such as the Bolton-Hunter reagent [8]. Bolton-Hunter
labeling is applicable to CCK since there is an alpha amino group present and
available for acylation, with structure-activity data supporting the possibility of
derivatization ofthat residue with multiple different chemical moieties [9].
Ofinterest, the first high specific radioactivity analog of CCK to be produced was
CCK-33, radioiodinated usingthe Bolton-Hunter reagent [10]. While this analogwas
initially used as a radioligand in radioimmunoassay, it is also useful as a receptor
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ligand. Indeed, it was subsequently used in both direct radioligand binding studies
and in affinity-labeling studies [7]. Subsequently, methodology for the acylation of
CCK-8 by Bolton-Hunter reagent was also reported [9]. Bolton-Hunter-labeled
CCK-8 has proven to be quite useful in CCK receptor-binding studies; however, the
absence of an available nucleophilic group in that molecule makes it unacceptable
for affinity labeling ofthe receptor.
A major advance occurred when it was appreciated that the two methionines
present within the carboxyl-terminal heptapeptide of CCK could be replaced with
threonines and/or norleucine, without interfering with receptor binding [11]. These
substitutions made the peptide stable to oxidative conditions, and potentially amena-
ble to oxidative radioiodination. Oxidative radioiodination is much preferable to the
acylation type of radiolabeling using Bolton-Hunter reagent, since it is less expen-
sive, more rapid, and provides a greater yield ofproduct. The latter, in particular, is
important for a technique such as affinity labeling, which utilizes avery large amount
ofradiolabeled probe.
A CCK analog in which the methionines were replaced with oxidation-resistant
residues was, therefore, further modified to incorporate a tyrosine on its amino
terminus [12]. Oxidative radioiodination of this peptide was successful, providing a
radiolabeled probe which bound to the receptor with appropriate affinity and
specificity [12]. That probe, however, as originally designed, was degraded quickly
when incubated with a protease-rich tissue such as pancreas. To overcome this
problem, a probe was designed inwhich unnecessary basic residues were eliminated,
and which incorporated a D-tyrosine at its amino terminus [13]. This process
provided an aminopeptidase-resistant probe which could be oxidatively radioiodin-
ated to high specific radioactivity while maintaining high-affinity binding to the CCK
receptor [13]. Also, unlike Bolton-Hunter-labeled CCK-8, this probe had an avail-
able alpha amino group for affinity labeling, using bifunctional cross-linking. This
probe hasbecome the template for a series ofadditional probes ofthe CCKreceptor
which our laboratory has developed.
AFFINITY LABELING OF THE CCK RECEPTOR
Affinity labeling has been a powerful method for the biochemical characterization
of sparse hormone receptors [14]. These molecules, although relatively few in
number, bind to ligand probes with high affinity and specificity. By incorporating a
high specific radioactivity radiolabel into the probe, this technique provides an
opportunity to radiolabel the receptor in a specific manner. In an affinity-labeling
experiment, the probe is allowed to bind to the receptor under optimal conditions,
and unbound probe is washed away. Then, using either bifunctional chemical
cross-linking reagents or a photolabile residue which may actually be incorporated
into the probe, covalent attachment is attempted. In the case of the use of bifunc-
tional cross-linking reagents, it is critical that an appropriately reactive group be
present and available in the radioligand probe. Even when that is the case, the
efficiencyofthis type ofcross-linkingistypicallyverylow, since the spatial approxima-
tion and geometry ofthat residue and an appropriate target residue on the receptor
are critical [15]. Using too high a concentration ofcross-linker may also result in the
serial attachment of several adjacent proteins, matting them together to provide a
misleading apparent size ofthe receptor complex. Photoaffinity labeling provides the
theoretical advantage of being more reactive, and therefore less selective, than the
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bifunctional chemical cross-linking reagents. In addition, by incorporating such a
reagent into the probe, only a single bond can be formed, and the possibility of the
serial cross-linking ofseveral adjacent proteins is eliminated.
All of these approaches have been used in the characterization of the pancreatic
CCK receptor. The initial report of specific affinity labeling using a CCK probe
utilized Bolton-Hunter-labeled CCK-33 and a series of bifunctional chemical and
photochemical cross-linkers [7]. In that work, the major membrane protein which
was consistently labeled migrated on a SDS-polyacrylamide gel as a broad band
around Mr = 80,000. Ofinterest is the fact that a number ofother proteins were also
labeled using this approach, but their labeling was not consistent from one cross-
linker to another. A protein of approximately Mr = 40,000 was present, linked via
disulfide bond to this Mr = 80,000 protein for part of the time. The observations of
these proteins in affinity labeling, using CCK-33-based probes, was subsequently
confirmed by other groups [16]. All ofthe traditional controls were satisfied by these
studies: namely, the labeling was inhibited in a concentration-dependent manner by
peptides structurally related to CCK, the labelingwas dependent on the presence of
cross-linker, and, in photoaffinity labeling, it was photolysis-dependent.
Because the receptor-binding domain of CCK is known to be present in its
carboxyl-terminal heptapeptide, far removed in primary sequence from the sites of
potential cross-linking using CCK-33-based probes (epsilon amino groups on lysines
in positions one and eleven), affinity labeling was then performed, using "shorter"
probes inwhich the site ofcross-linkingwas adjacent to thispharmacophoric domain
[13,17]. For this procedure, the oxidatively labeled short CCK receptor probes
discussed above were used. Though this work was originally performed as a control
experiment, to confirm the identity of the Mr = 80,000 protein as the CCK-binding
subunit ofthe receptor, it surprisingly identified a distinct protein of apparent Mr =
85,000-95,000 [17]. This finding proved true, using a series ofshort probes [18]. The
distinct nature ofthese twoproteinswas furtherdocumented in studies inwhichboth
were deglycosylated to yield protein cores of different size [19] and in studies in
which the protein coreswere mapped, using specific proteases [20]. The Mr = 80,000
protein originally described appears to have a core protein ofMr = 65,000 [21], while
the Mr = 85,000-95,000 protein, first identified using the shorter probes, appears to
have a core protein ofMr = 42,000 [17].
While the two affinity-labeled proteins which were thought to be candidates to
represent the pancreatic CCK receptor were clearly distinct, there was still a
question as to which was the most likely candidate to represent the CCK-binding
protein. Our bias was that the protein labeled when the site of cross-linking was
closest to the receptor-binding domain was most likely to represent that protein. In
order to test this hypothesis experimentally, new probes were developed, which
incorporated photolabile residues for photoaffinity labelingwithin, or "intrinsic" to,
the receptor-binding domain. Three such probes were developed, which utilized
nitro- or azido-aromatic residues in positions of native aromatic residues within the
pharmacophoric domain of CCK [22,23]. These probes included '251-D-Tyr-Gly-
[(Nle28'31, pN3-Phe33)CCK-26-33], 1251-D-Tyr-Gly-[(Nle28'31,pNO2-Phe33)CCK-26-33],
and '25I-D-Tyr-Gly-[(Nle28'31, 6-NO2-Trp30)CCK-26-33]. The structures of two of
these probes appear in Table 1. These were shown to be fully efficacious pancreatic
secretagogues, which interacted specifically with the CCK receptor. The photolabil-
ity of the modified aromatic residues was documented, and the ability to activate
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TABLE 1
Some ofthe Substitutions in the Structure of Native CCK
CCK Analogues
Asp-Tyr(SO3)-Met-Gly-Trp-Met-Asp-Phe(NH2)
Oxidation resistant
"Short"
"Intrinsic"
-Nle-
[1261].T _-Gly-
[1'25ITyr-Gly-
[1'25lTyr-Gly-
"Topographical mapping"
NPA----PEGn---['2J11Tyr-Gly-
-Nle-
-Nle-
(NO2)
-Nle- -ip-Nle-
-Nle- -Nle-
These substitutions yield receptor probes which bind with appropriate specific-
ity and high affinity, which can be radioiodinated to high specific radioactivity, and
which are cross-linkable and/or photolabile (through residues shown in italics and
underlined).
these specifically upon photolysis with a 300 nm lamp was established. All of these
probes affinity-labeled the same Mr = 85,000-95,000 pancreatic plasma membrane
glycoprotein with protein core of Mr = 42,000 [22,23] (Fig. 1). This result was
interpreted as confirmation that this protein represented the hormone-binding
subunit of the CCK receptor. It was postulated that the Mr = 80,000 protein
originally identified was associated with this protein, since it was clear that it
represented a minor membrane protein, which was specifically labeled by a number
1'2rI-CCK 32 p
Endo F
85-95 _~
co
'x 42*0
FIG. 1. Autoradiographs of typical
SDS-polyacrylamide gels used to sepa-
rate products of affinity labeling the
rat pancreatic CCK receptor (left) or
phosphorylating this molecule (right).
Shown are lanes in which the mature
(Mr = 85,000-95,000) and degly-
cosylated (Mr = 42,000) proteins are
separated.
Native CCK-8
-Nle-
-Nle-
(NO2)
-Nle- -Eb&(NH2)
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ofdifferent laboratories. That labeling could not be attributed solely to artifact or to
the chance association ofa prominent membrane protein.
To explore further the possible spatial association between the two affinity-labeled
proteins, "topographical mapping" probes were designed and synthesized [24].
These probes were designed to separate the receptor-binding domain of the probe
from a photolabile residue by a variable-length flexible spacer. For this spacer, we
used poly(ethyleneglycol) (PEG), which is known to assume a random coil and not to
interfere with the native conformation of associated peptides. The polymeric nature
ofthis reagent made it easy tovary the length ofthe spacer in a systematic manner. It
was postulated that the probes with the shortest spacers would label only the
CCK-binding subunit, while associated subunits would be labeled when the spacer
attained the appropriate length to reach it. Indeed, the shortest such probes labeled
only the pancreatic plasma membrane glycoprotein with apparent Mr = 85,000-
95,000, which has a protein core of Mr = 42,000. It was only when the probe
incorporated the polymeric spacer with ten ethyleneglycol monomer units (approxi-
mately 16.2A) that the Mr = 80,000 protein began to be labeled [24].
These data are consistent with the Mr = 85,000-95,000 protein representing the
CCK-binding subunit of the receptor, with an associated Mr = 80,000 protein. The
CCK receptor is now known to represent a guanine nucleotide-binding protein (G
protein)-associated receptor, with seven transmembrane segments predicted [25].
There is no current precedent for an additional protein to be associated with such a
receptor protein, and it is clear from expression cloning that a single protein in this
family is capable ofbinding ligand normally, associatingwith its guanine nucleotide-
binding protein, and initiating intracellular activation cascades. If this association
holds true, it may be possible that the associated protein could play a role in
regulation of receptor function, such as modulation of the biological response or
binding of the hormone. Studies of such a protein will be dependent on its further
purification and characterization.
APPROACHES TO DEFINE POST-TRANSLATIONAL MODIFICATIONS
AND RECEPTOR DOMAINS
In addition to the identification of the pancreatic CCK receptor and potentially
associated proteins, methods of working with the mature, naturally expressed
receptor such as affinity labeling have been able to demonstrate directly additional
structural features of the receptor which cDNA cloning can only predict. Included
among these features are the possibilities of the post-translational modifications of
receptor glycosylation and receptorphosphorylation.
Glycosylation may be studied by removal of the carbohydrate from the mature
receptor, using chemical or enzymatic methods. The enzymatic approach has the
potential advantage of being specific for certain types of carbohydrate and certain
linkages. By using limited amounts of enzyme and separating the products of
receptor deglycosylation, it has also been possible to predict the number ofcarbohy-
drate chains associated with the receptor. Both the Mr = 85,000-95,000 and the Mr =
80,000 proteins have been shown to be complex, N-linked (via asparagine residues)
sialoglycoproteins with three or more carbohydrate chains [19,21]. Neitherglycopro-
tein hasbeen demonstrated to have 0-linked carbohydrate, although a small amount
ofthis type cannot be fully excluded.
Receptor phosphorylation has been demonstrated by biosynthetic labeling of the
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receptor in the intact cell after radiolabeling the ATP pool with 32p [26] (Fig. 1).
Using affinity adsorption methods developed and validated with affinity-labeled
pancreatic CCK receptor, it was possible to demonstrate that the CCK receptor was
phosphorylated in response to agonist stimulation; this process was appropriately
blocked by CCK receptor antagonists. Also, increased receptor phosphorylation was
observed after stimulation of the pancreatic acinar cells with heterologous agonists,
which are known to act via intracellular cascades similar to those initiated by CCK
[26]. Agents such as carbamylcholine and TPA have been shown to elicit heterolo-
gous desensitization ofthe CCKreceptor, awell-described general effect ofreceptor
phosphorylation. There are preliminary data to support the existence of at least two
pancreatic enzymes which phosphorylate the CCK receptor in vivo. Investigation of
the identityofthese enzymes, their sitesofaction, theirregulation, and the biological
effects oftheir action are in progress.
Perhaps the most unique and important contribution to our understanding of
receptor structure and function possible with affinity labeling is the use of this
technique for the direct identification ofthe hormone-binding domain ofa receptor.
It is even theoretically possible to identify specific interacting residues within the
receptor, using this approach. The development of "intrinsic" affinity-labeling
probes, with a photolabile residue within the pharmacophoric domain ofthe ligand,
as described above, is the first step toward this goal [22,23]. Using those probes and
proteolytic cleavage ofthe labeled receptor, it hasbeen possible to identify a general
domain of the receptor on which to focus [20]. With the current availability of
primary sequence information about receptors in this family, it should be possible to
extend this "active sitemapping" to ahigherlevel ofdetail. Thisgoalwill also require
the development ofadditional, more reactive "intrinsic" probes.
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